Related references
Note: Only part of the references are listed.A systematic review of economic evaluations of advanced therapy medicinal products
Huw Lloyd-Williams et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment Implications
Melanie D. Whittington et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas
Caron A. Jacobson et al.
BLOOD ADVANCES (2020)
A review of spline function procedures in R
Aris Perperoglou et al.
BMC MEDICAL RESEARCH METHODOLOGY (2019)
Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy
Michael F. Drummond et al.
VALUE IN HEALTH (2019)
Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System
Casey Quinn et al.
VALUE IN HEALTH (2019)
Modelling uncertainty in survival and cost-effectiveness is vital in the era of gene therapies: the case of axicabtagene ciloleucel
Adam J. N. Raymakers et al.
HEALTH POLICY AND TECHNOLOGY (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
International HTA Experience with Targeted Therapy Approvals for Lung Cancer
Fatma Maraiki et al.
PHARMACOECONOMICS-OPEN (2019)
Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma
Qiushi Chen et al.
LEUKEMIA & LYMPHOMA (2018)
Gene Therapy and Genome Editing
Farid Boulad et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies
Melanie D. Whittington et al.
JAMA PEDIATRICS (2018)
What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia?
Christopher R. Flowers et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal
Robert Hettle et al.
HEALTH TECHNOLOGY ASSESSMENT (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies
Amr Makady et al.
VALUE IN HEALTH (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Arend von Stackelberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Using Nonrandomized Studies to Inform Complex Clinical Decisions: The Thorny Issue of Cranial Radiation Therapy for T-Cell Acute Lymphoblastic Leukemia
Michael J. Kelly et al.
PEDIATRIC BLOOD & CANCER (2015)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Gene therapy on the move
Kerstin B. Kaufmann et al.
EMBO MOLECULAR MEDICINE (2013)
Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia
Nobuko Hijiya et al.
BLOOD (2011)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
David Moher et al.
INTERNATIONAL JOURNAL OF SURGERY (2010)
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia
S Jeha et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)